Lyell Immunopharma Inc at Goldman Sachs Healthcare Conference Transcript
Good morning. It's my pleasure to introduce with us Dr. Lynn Seeley, President and CEO of Lyell Therapeutics.
Questions & Answers
Lynn, to start here, could you give us an overview of where your two oncology programs stand today and how to think about the catalyst path as we look to the second half and beyond?
Absolutely. Well, I will be making forward-looking statements here today. So Lyell is a cell therapy company focused on next-generation cell therapies for cancer. And we have two programs in the clinic. One is a dual targeting CD19/CD20 CAR T-cell program for large B-cell lymphoma where we are in pivotal trials. We have a single arm pivotal trial underway where we're going to be providing a major data update in the second half of this year. That will be the last look before the pivotal data are expected in the next year, and then we'll be following that with an expected BLA submission
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
